22UA:ETR
BioNTech SE - ADR
€85.25
arrow_upward
+1.91%(+1.60) 1D
Sep 17, 3:42:09 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€84.30
High
€85.35
Low
€83.70
Mkt. cap
24.90B
Avg. vol.
52.83K
Volume
5.24K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€84.30
High
€85.35
Low
€83.70
Mkt. cap
24.90B
Avg. vol.
52.83K
Volume
5.24K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
Investing.com
·
1 day ago
UBS reiterates Buy on BioNTech stock after lung cancer data
Yahoo Finance
·
1 day ago
BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
Mugglehead Investment Magazine
·
2 days ago
BioNTech’s lung cancer drug outperforms chemo in clinical study
Yahoo Finance
·
2 days ago
Why Is BioNTech Stock Gaining Monday?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR